SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

ARGONAUT TECHNOLOGIES, INC.

220 Saginaw Drive
Redwood City, CA 94063
(Address of principal executive offices, including zip code)

(650) 716-1600
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ   No o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).
Yes o   No þ

There were 20,685,050 shares of the registrant’s common stock outstanding on October 31, 2004.

Page 1 of 23

Argonaut Technologies, Inc.
Form 10-Q
Quarterly Period Ended September 30, 2004

TABLE OF CONTENTS

Page 2 of 23

PART I: FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ARGONAUT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 3 of 23

ARGONAUT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 4 of 23

ARGONAUT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 5 of 23

ARGONAUT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — BASIS OF PRESENTATION AND NEW ACCOUNTING STANDARDS

Basis of presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not contain all of the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of normal recurring accruals and adjustments, which Argonaut Technologies, Inc. (“Argonaut” or “the Company”) considers necessary to present fairly the financial information included herein. The condensed consolidated balance sheet at December 31, 2003 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Form 10-K, for the year ended December 31, 2003 as filed with the Securities and Exchange Commission. The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2004, or any other future period.

Product Warranty

The Company generally warrants its equipment for a period of one year and provides a reserve for estimated warranty costs concurrent with the recognition of revenue. The Company also sells warranty extensions and the related revenue is recognized ratably over the term of the extension. Warranty costs incurred during the extension period are expensed as incurred.

Changes in the Company’s product warranty accrual for the nine months ended September 30, 2004 and 2003 are as follows (in thousands):

New Accounting Standards

On October 13, 2004, the Financial Accounting Standards Board (“FASB”) concluded that Statement 123R, “Share-Based Payment,” (“Statement 123R”) which would require all companies to measure compensation cost for all share-based payments at fair value, would be effective for most public companies for interim or annual periods beginning after June 15, 2005. Argonaut will be required to apply Statement 123R beginning July 1, 2005 and could choose to apply Statement 123R retroactively from January 1, 2005 to June 30, 2005. The Company is in the process of analyzing Statement 123R and its stock-based compensation information to determine whether it will apply the Statement prospectively or retroactively. The cumulative effect of adoption, if any, would be measured and recognized on July 1, 2005.

NOTE 2 — STOCK-BASED COMPENSATION

The Company accounts for its stock-based employee compensation as permitted by Statement of Financial Accounting Standard No. 123, “Accounting for Stock-Based Compensation” (“SFAS 123”), as amended by Statement of Financial Accounting Standard No. 148, “Accounting for Stock-Based Compensation – Transition and Disclosure,” whereby stock-based employee compensation arrangements are accounted for under the intrinsic value method prescribed by Accounting

Page 6 of 23

Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (“APB 25”). Under APB 25, when the exercise price of the Company’s stock options is less than the market price of the underlying shares on the date of grant, compensation expense is recognized. Pro forma information regarding net loss per share is required by SFAS 123 as if the Company had accounted for its employee stock options under the fair value method of SFAS 123. The fair value of these options granted prior to the Company’s initial public offering in July 2000 was estimated at the date of grant using the minimum value method. The fair value of stock options granted subsequent to the initial public offering were valued using the Black-Scholes valuation model based on the actual stock closing price on the date of grant. The fair value of these options was estimated at the date of grant using the following weighted-average assumptions:

The pro forma disclosures required by SFAS 123 are as follows (in thousands, except per share amounts):

Equity instruments granted to non-employees are accounted for using the Black-Scholes valuation model prescribed by SFAS 123 and, in accordance with Emerging Issues Task Force Consensus No. 96-18, “Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring or in Conjunction with Selling Goods or Services.” The equity instruments are subject to periodic revaluations over their vesting terms. The expense is recognized as the instruments vest.

NOTE 3 — INVENTORIES

Inventories consist of the following (in thousands):

Page 7 of 23

NOTE 4 — NET LOSS PER SHARE

Net loss per share has been computed according to Statement of Financial Accounting Standards (SFAS) No. 128, “Earnings Per Share,” which requires disclosure of basic and diluted earnings per share. Basic and diluted net loss per share was computed using the weighted-average number of common shares outstanding during the period. Due to the net loss position of the Company, diluted earnings per share is calculated using the weighted average number of common shares outstanding and excludes the effects of potential common shares that are antidilutive. Options to purchase 3,334,676 and 3,910,832 shares of common stock were outstanding at September 30, 2004 and September 30, 2003, respectively. Warrants to purchase 63,065 and 80,665 shares of common stock were outstanding at September 30, 2004 and September 30, 2003, respectively. Options and warrants were not included in the computation of diluted net loss per share, since the effect would be antidilutive.

NOTE 5 — COMPREHENSIVE LOSS

Comprehensive loss is comprised of net loss and other items of comprehensive income (loss). Other comprehensive income (loss) includes unrealized gains and losses on the Company’s short-term investments and foreign currency translation adjustments.

For the three- and nine-month periods ended September 30, 2004 and 2003, comprehensive loss is as follows (in thousands):

NOTE 6 — GOODWILL AND OTHER PURCHASED INTANGIBLES

Goodwill and other purchased intangible assets with indefinite lives have resulted from the acquisition of Camile Products, LLC (now Argonaut Technologies Systems, Inc. (“ATSI”)) and Jones Chromatography Limited (“the Jones Group”). Goodwill and other intangible assets with indefinite lives are not amortized subsequent to the Company’s adoption of SFAS 142, “Goodwill and Other Intangible Assets” (“SFAS 142”).

All goodwill and intangible assets have been assigned to one of two reporting units. The Argonaut (“AGNT”)-Legacy reporting unit consists primarily of goodwill and intangible assets related to the Company’s acquisition of ATSI. The Jones-Group reporting unit consists of goodwill and intangible assets deriving from the Company’s acquisition of Jones Chromatography, Ltd.

During the third quarter ended September 30, 2003 the Company performed an interim test for goodwill impairment in light of lower than expected third quarter revenue. Based on the discounted cash flows of the AGNT-Legacy reporting unit, the Company recognized an impairment charge of $1.6 million relating to the goodwill and intangible assets associated with ATSI. Approximately $763,000 of the impairment charge was related to goodwill associated with ATSI, and the remainder was related to completed technology assets associated with the acquisition of ATSI.

The Company performed the annual test for impairment of intangible assets with indefinite lives as prescribed by SFAS 142 during the fourth quarter of fiscal 2003, determining that no further impairment was indicated. The Company determined the fair value of intangible assets with indefinite lives based on a present value analysis of the discounted future cash flows. The Company plans to perform the impairment test in the fourth quarter of 2004. As of September 30, 2004, the Company does not have any intangible assets with indefinite lives.

The amortization expense relating to the intangible assets for the three- and nine-month periods ended September 30, 2004 was $163,000 and $473,000, respectively. The following represents the gross carrying amounts and accumulated amortization of amortized intangible assets at September 30, 2004:

Page 8 of 23

Estimated future amortization expense related to intangible assets at September 30, 2004 is as follows (in thousands):

NOTE 7 — RESTRUCTURING CHARGES

On August 8, 2002, the Company announced its intention to execute a restructuring program focused on improving productivity, reducing operational expenses in remote offices, and implementing a workforce reduction of approximately 20% of its existing worldwide employees. As of September 30, 2004, all of the 44 employees had been terminated and amounts related to the abandonment of excess leased facilities have all been paid.

A summary of the restructuring activity is as follows (in thousands):

NOTE 8 – DEBT REPAYMENT

The restricted cash of approximately $12.2 million that served to secure the notes payable as purchase consideration of the Jones Group was used during the second quarter of 2004 to repay those notes in full.

Page 9 of 23

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This quarterly report contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, and it is the Company’s intention that such statements be protected by the safe harbor created thereby. Examples of such forward-looking statements include statements regarding future revenues, expenses, losses and cash flows, research and development activities, possible future acquisitions, our plans to discontinue non-performing consumable products and certain legacy instrument products, values of our assets and liabilities over their remaining useful lives and our testing for impairment of goodwill, and our expectations as to the duration of our negative cash flows from operations and the sufficiency of existing cash reserves for the next 12 months. Actual results may differ materially from those projected in such forward-looking statements due to various known and unknown risks and uncertainties, including the risk that a decline in the economy generally or the market for our products will adversely affect our business, the risk that the market for our products and services does not develop as anticipated. For a further discussion of these and other risks and uncertainties related to our business see the discussion set forth herein under “Factors That May Affect Our Future Results.”

Overview

Argonaut develops innovative products designed to help pharmaceutical and other chemists engaged in the discovery and development of new chemical entities increase their productivity and reduce their operating costs without compromising the scientific integrity of their research. Our products are designed to enable chemists to increase their productivity, reduce their operating costs through automation and process simplification, and cost effectively explore the increasing number of drug targets available for drug development. We derive revenues primarily from the sale of our chemistry consumable products, instrumentation products and services. We also derive revenues from the sale of reagents, and other instrument-related consumables and consumables products of Jones Chromatography Limited (“Jones Group”), which we acquired on February 20, 2002. Our expenses have consisted primarily of costs incurred in research and development, manufacturing and general and administrative costs associated with our operations, and our sales and marketing organization. Since our inception, we have incurred significant losses and, as of September 30, 2004, we had an accumulated deficit of $85.3 million.

Recent Developments

Headquarter relocation

During the third quarter of 2004, the Company moved its corporate headquarters to Redwood City, CA from Foster City, CA and relocated one of its an ancillary offices. The new facility in Redwood City allows the Company to operate its manufacturing operations more efficiently. Moreover, the Company estimates that future cost savings of $800,000 to $900,000 should be realized from the relocation of both its corporate headquarters and the ancillary office.

New product introduction

In the first quarter of 2004, we launched the FlashMaster Personal+ system and the Advantage Series 2410 personal screening synthesizer. Both of these products are important to our ability to increase revenues in 2004 and beyond. Designed for use with pre-packed, disposable ISOLUTE® flash chromatography columns, the FlashMaster Personal+ system features a second column position for on-line solid sample loading and a liquid injection port for soluble samples. The 2410 personal screening synthesizer is designed to help process chemists who work with small amounts of material, simulate and replicate the thermal and mixing conditions seen in larger production reactors.

Recently, we launched the ISOLUTE® PPT+ Protein Precipitation Plate. Protein precipitation filterplates are used to remove unwanted components from biological fluids before they are analyzed by LC-MS. Sample preparation using ISOLUTE® PPT+ is based on a “solvent first” method which does not require mixing and yields cleaner and more dependable results than competitive methods. Commercialization of ISOLUTE PPT+ represents the first in a series of products under development for the bio-analytical sample preparation market.

Critical Accounting Policies

There have been no material changes to the Company’s critical accounting policies that are included/described in our Form

Page 10 of 23

10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission on March 30, 2004.

RESULTS OF OPERATIONS FOR THE THREE- AND NINE- MONTH PERIODS ENDED SEPTEMBER 30, 2004

Net Sales
Net sales in the three-month period ended September 30, 2004 were $4.8 million compared to $5.2 million for the same period in 2003, a decrease of 7%. The decrease in net sales is primarily due to the discontinuation of certain non-strategic product lines during 2003, the winding down of a contract research and development (“R&D”) project, and decreased integration services sales. For the third quarter of 2004, instrument sales comprised approximately 26% of net sales, chemistry consumables sales comprised approximately 54% of net sales, and service, integration services and contract R&D together comprised approximately 20% of net sales. Instrument sales were $1.3 million in the third quarter of 2004 versus $1.5 million for the same period in 2003, primarily due to the discontinuation of certain product lines during 2003. Chemistry consumables sales were $2.6 million in the third quarter of 2004 compared to $2.7 million for the same period in 2003. Sales of current products increased approximately 4% in the third quarter of 2004 but were offset by lower revenue from discontinued products. Service, integration services and contract R&D sales were $948,000 in the third quarter of 2004 versus $999,000 in the same period of 2003, a decrease of about 5%. The decline is primarily due to the winding down of a contract R&D project and lower service revenue. For the nine-month period ended September 30, 2004, instrument sales were $4.5 million or 30% of total net sales, versus $6.1 million, or 33% of total net sales for the same period in 2003 due primarily to the effects of product transitions. Chemistry consumable sales for the nine-month period ended September 30, 2004 were $8.0 million versus $9.0 million in the same period in 2003, a decrease of 11%. The decline is primarily attributable to the sale of certain product lines to a third party.

Cost of sales
Gross margin as a percent of sales was 16.5% for the third quarter of 2004 compared to 50.5% for the third quarter of 2003. For the nine-month period ended September 30, 2004, gross margin as a percent of sales was 30.1% as compared to 45.8% for the same period in 2003. Lower margin performance in the third quarter was primarily the result of recording a charge of approximately $1.1 million for the write-down of discontinued and slow moving inventory and additional costs incurred related to our integration service revenue. For the nine-month period ended September 30, 2004, the lower margin is attributable to the events of the third quarter and the fact that lower revenue did not support the relatively fixed manufacturing costs. In addition, during the first quarter of 2004, we incurred costs of approximately $211,000 due to the transfer of the manufacturing of our flash chromatography instrument business from Cardiff, Wales to Foster City, California and the transfer of a chemistry resins business from Foster City to Cardiff. Further, there was also an additional inventory write-off of approximately $120,000 due to excess and obsolete inventory.

Research and development expenses
Research and development expenses of $1.1 million for the three-month period ended September 30, 2004 remained about the same compared to the same period in 2003. These expenses include salaries and related costs of research and development personnel, fees paid to consultants and outside service providers, the costs of facilities and related expenses, non-recurring engineering charges and prototype costs related to the design, development testing, pre-manufacturing and significant improvement of our products. For the nine-month period ended September 30, 2004, research and development expenses decreased to $3.0 million from $3.4 million, a decrease of 12%, primarily due to lower personnel costs, along with lower outside services and engineering supplies expense.

Selling, general and administrative expenses
Selling, general and administrative expenses increased to $3.1 million in the three-month period ended September 30, 2004 from $2.8 million for the same period in 2003, an increase of 9%. These expenses consist primarily of salaries and related costs for executive, sales and marketing, finance and other administrative personnel, the cost of facilities and related spending, and the costs associated with promotional and other marketing expenses. The increase was primarily attributable to higher legal fees and outside services expense. Selling, general and administrative expenses decreased to $9.4 million for the nine-month period ended September 30, 2004 from $10.4 million, a decrease of 10%. The decrease was due primarily to lower personnel costs and lower costs associated with promotional activities, offset by higher legal fees and outside services expense.

Restructuring charges
On August 8, 2002, the Company announced its intention to execute a restructuring program focused on improving productivity, reducing operational expenses in remote offices, and implementing a workforce reduction of approximately 20% of the existing worldwide employees. As a result, the Company recognized a charge of $1.8 million in the third quarter

Page 11 of 23

ended September 30, 2002. The charge included termination benefits and related expenses of approximately $630,000 related to the reduction of our workforce by 44 employees, expenses of approximately $683,000 related to the abandonment of excess equipment, expenses of approximately $356,000 for the abandonment of excess leased facilities, and expenses of approximately $133,000 for various related charges. The restructuring program is estimated to result in annualized savings of approximately $3.0 million beginning in fiscal 2003, realized primarily in reduced operating costs as a result of reduced employee-related costs. As of September 30, 2004, all of the 44 employees had been terminated. For the three and nine months ended September 31, 2004, there were $22,000 and $153,000 of cash payments related to the restructuring program, respectively. Amounts related to the abandonment of excess leased facilities have all been paid as of September 30, 2004.

Amortization of purchased intangible assets
For the quarter ended September 30, 2004, as part of operating expenses, the Company recorded amortization of purchased intangibles of $129,000 compared to $202,000 in the same period in 2003. For the nine-month period ended September 30, 2004, the Company recorded amortization of purchased intangibles of $370,000 compared to $627,000 for the same period in 2003. The decrease in amortization expense for both periods is due to the lower carrying value of the purchased intangible assets, as a result of an impairment write-off made in September 2003.

Interest and Other Income (Expense), net
Interest and other income decreased to $125,000 for the three-month period ended September 30, 2004 as compared to $172,000 for the same period in 2003, primarily because of lower interest income due to lower cash balances invested. Interest and other expense was $16,000 for the third quarter of 2004 compared to $173,000 in the same period in 2003, primarily due to lower interest expense as the notes payable for the Jones Group acquisition were repaid in full during the quarter ended June 30, 2004. For the nine-month period ended September 30, 2004, interest and other income decreased to $441,000 as compared to $704,000 for the same period in 2003 due to the same factors contributing to the results for the third quarter. Interest and other expense was $195,000 for the first nine months of 2004 as compared to $499,000 for the same period in 2003.

Provision for Income Taxes
The Company recorded a provision for income taxes of approximately $42,000 and $23,000 for the UK corporate tax liability of Jones Group for the three and nine months ended September 30, 2004, respectively, as compared to approximately $420,000 and $531,000 for the same periods in 2003.

LIQUIDITY AND CAPITAL RESOURCES

As of September 30, 2004, the Company had cash, cash equivalents, investments and restricted cash of $11.9 million compared to $31.2 million at December 31, 2003. The decrease was primarily due to the use of $6.4 million in general operating activities, repayment of the notes payable, using restricted cash of approximately $12.2 million related to the acquisition of the Jones Group and $0.8 million used for capital expenditures.

Restricted cash of $0.3 million at September 30, 2004 represents deposits against operating leases. The restricted cash of approximately $12.2 million that served to secure the notes payable as purchase consideration of the Jones Group was used during the second quarter of 2004 to repay those notes in full.

Net cash used to support operating activities has historically fluctuated based on the timing of payments of accounts payable balances, receipts of customer deposits, receipt of payments of accounts receivable balances, changes in inventory balances resulting from varying levels of manufacturing activities, the timing of research and development projects, the timing and scope of our sales and marketing initiatives and fluctuations in the Company’s net loss.

On August 8, 2002, the Company announced the approval by its Board of Directors of a stock repurchase program pursuant to which shares of its outstanding common stock having an aggregate value of up to $500,000 may be repurchased through open market transactions at prices deemed appropriate by the Company. The duration of the stock repurchase program is open-ended. The timing and amount of repurchase transactions under this program will depend on market conditions, corporate and regulatory considerations, and will be funded from available working capital. During the nine months ended September 30, 2004, the Company repurchased 50,000 shares of its common stock on the open market for approximately $81,000 at an average price of $1.62 per share. Through September 30, 2004, the Company had repurchased 100,000 shares of its outstanding common stock at an average price of $1.28, pursuant to our stock repurchase program.

The Company expects to have negative cash flows from operations through the fourth quarter of 2004 and into 2005. We may also use cash resources to fund additional collaborative or strategic relationships, acquisitions or investments in other

Page 12 of 23

businesses, technologies or product lines. Based on our current expectations, we believe that our current cash balances will be sufficient to fund our operations through at least the next 12 months.

At September 30, 2004, there have not been any substantial changes to the Company’s contractual cash obligations from those reported at December 31, 2003.

New Accounting Standards

On October 13, 2004, the FASB concluded that Statement 123R, “Share-Based Payment,” (“Statement 123R”) which would require all companies to measure compensation cost for all share-based payments at fair value, would be effective for most public companies for interim or annual periods beginning after June 15, 2005. Argonaut will be required to apply Statement 123R beginning July 1, 2005 and could choose to apply Statement 123R retroactively from January 1, 2005 to June 30, 2005. The Company is in the process of analyzing Statement 123R and its stock-based compensation information to determine whether it will apply the Statement prospectively or retroactively. The cumulative effect of adoption, if any, would be measured and recognized on July 1, 2005.

FACTORS THAT MAY AFFECT OUR FUTURE RESULTS

We have a history of operating losses and we may never achieve or sustain profitability and may be required to raise additional funds if losses continue.

We have incurred operating losses and negative cash flows from operations since our inception. As of September 30, 2004, we had an accumulated deficit of $85.3 million and we recorded a net loss of $8.0 million for the nine-month period ended September 30, 2004. We expect to continue to incur operating and net losses through the fourth quarter of 2004 and into 2005 and we may never generate positive cash flows.

Our future capital requirements depend on a number of factors, including market acceptance of our products, the resources we devote to developing and supporting our products, continued progress of our research and development of potential products, the need to acquire licenses to new technology and the availability of other financing on acceptable terms. To the extent that our capital resources are insufficient to meet future capital requirements, we will need to raise additional capital or incur indebtedness to fund our operations. To the extent that we raise additional capital through the sale of equity, the issuance of those securities will result in dilution to our stockholders. There can be no assurance that additional debt or equity financing will be available on acceptable terms, if at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate, our operations. We may be required to obtain funds through arrangements with collaborative or strategic partners or others that may require us to relinquish rights to certain technologies or products that we might otherwise seek to retain.

If our products do not become widely used in the pharmaceutical, biotechnology, life sciences and chemical industries, it is unlikely that we will ever become profitable.

Pharmaceutical, biotechnology, life sciences and chemical organizations have historically performed chemistry development using traditional laboratory methods. To date, our products have not been as widely adopted by these industries as we had expected. The commercial success of our products will depend upon the adoption of these products as a method to develop chemical compounds for these industries. In order to be successful, our products must meet the performance and pricing requirements for chemistry development within the pharmaceutical, biotechnology, life sciences and chemical industries. Market acceptance will depend on many factors, including our ability to:

•		Convince prospective customers that our products are a cost-effective alternative to traditional methods and other technologies that may be introduced for chemistry development.
•		Convince prospective customers that our products provide the same or enhanced quality and accuracy as compared with traditional methods and other new technologies that may be developed.
•		Manufacture products in sufficient quantities with acceptable quality and at an acceptable cost.
•		Install and service sufficient numbers of our instruments, particularly new instruments such as the Advantage Series™ 3400 process chemistry workstation.
•		Convince prospective customers that our products and our ability to supply and support our products are equivalent or better as compared to competitor companies.

Page 13 of 23

If we cannot achieve these objectives, our products will not gain market acceptance.

Our product development efforts may not produce commercially viable products.

We continue to devote significant personnel and financial resources to research and development activities to develop new products. We may not be successful in developing new products, and we may never realize any benefits from such research and development activities, which may not produce commercially viable products. Our ability to increase our revenues and achieve and sustain profitability is dependent upon our ability to successfully develop new and commercially viable products. During the first half of 2003, we launched a new product, the Advantage Series™ 3400 workstation and in the first half of 2004, we launched the FlashMaster Personal+ system and the Advantage Series 2410 personal screening synthesizer. Our ability to increase revenues in 2004 and beyond is dependent on the success of these products.

Our instrument products have lengthy sales cycles, which could cause our operating results to fluctuate significantly from quarter to quarter.

Our ability to obtain customers for our instrument products depends, in significant part, upon the perception that our products can help accelerate efforts in chemical development. The sale of many of our instrument products typically involves a significant technical evaluation and commitment of capital by customers. Accordingly, the sales cycles of many of our instrument products are lengthy and subject to a number of risks that are beyond our control, including customers’ budgetary constraints and internal acceptance reviews. Our revenues could fluctuate significantly from quarter to quarter, due to this lengthy and unpredictable sales cycle. A large portion of our expenses, including expenses for facilities, equipment and personnel, are relatively fixed. Accordingly, if our revenues decline or do not grow as we anticipate, we might not be able to correspondingly reduce our operating expenses. Our failure to achieve our anticipated levels of revenues could significantly harm our operating results for a particular fiscal period. Due to the possibility of fluctuations in our operating results, we believe that quarter-to-quarter comparisons of our operating results are not always a good indication of our future performance.

The capital spending policies of pharmaceutical, biotechnology, life sciences and other chemical research organizations have a significant effect on the demand for our instruments.

We market our products to and receive our revenues principally from pharmaceutical, biotechnology, life sciences and other chemical research organizations, and the capital spending policies of these entities can have a significant effect on the demand for our instruments. These policies are based on a wide variety of factors, including the resources available for purchasing research equipment, the spending priorities among various types of research equipment and the policies regarding capital expenditures. In particular, the volatility of the public stock market for biotechnology and related companies has at certain times significantly impacted their ability to raise capital, which has directly affected their capital spending budgets. In addition, continued consolidation within these industries will likely delay and may potentially reduce capital spending by pharmaceutical companies involved in such consolidations. Any decrease or delay in capital spending by life sciences companies could cause our revenues to decline and harm our profitability.

Our direct worldwide sales force and network of distributors may not be sufficient to successfully address the market for our products.

We sell a major portion of our products through our own sales force. We may not be able to build an efficient and effective sales and marketing force and continue to expand our network of distributors. Our failure to build an efficient and effective sales and marketing force could negatively impact sales of our products, thus reducing our revenues and profitability.

In order to be successful, we must recruit, retain and motivate key employees, and failure to do so could seriously harm us.

In order to be successful, we must recruit, retain and motivate executives and other key employees, including those in managerial, technical, marketing and sales positions. In particular, our product generation efforts depend on hiring and retaining qualified technical personnel. Attracting and retaining qualified sales representatives is also critical to our future. Experienced management and technical, marketing and support personnel in the chemistry instrumentation and consumables industry are in high demand and competition for their talents is intense, although current economic conditions have moderated this demand and competition for talent. The loss of key employees could have a significant impact on our operations. We also must continue to motivate employees and keep them focused on Argonaut’s strategies and goals, which

Page 14 of 23

may be particularly difficult due to morale challenges posed by workforce reductions and general uncertainty. Changes in management may be disruptive to our business and may result in the departure of existing employees, customers and/or research collaborators. It may take significant time to locate, retain and integrate qualified management personnel.

The life sciences industry is highly competitive and subject to rapid technological change, and we may not have the resources necessary to successfully compete.

We compete with companies worldwide that are engaged in the development and production of similar products. We face competition primarily from the following three sectors:

•

pharmaceutical companies developing their own instruments;

•

companies marketing products based upon parallel synthesis and other non-traditional technologies, such as Mettler-Toledo AG and several smaller instrument and reagent companies; and

•

companies marketing conventional products based on traditional chemistry methodologies, such as Biotage AB, and Isco, Inc.

Many of our competitors have access to greater financial, technical, research, marketing, sales, distribution, service and other resources than we do. We face, and will continue to face, intense competition from organizations serving the life sciences industry that are developing or marketing competing products and technologies. These organizations may develop products or technologies that are superior to our products or technologies in terms of performance, cost or both. These organizations may offer price discounts or other concessions as a competitive tactic that we may not be in a position to match.

We will need to develop new applications for our products to remain competitive. Our present or future products could be rendered obsolete or uneconomical by technological advances of one or more of our current or future competitors. In addition, the introduction or announcement of new products by us or by others could result in a delay of or decrease in sales of existing products, as customers evaluate these new products. Our future success will depend on our ability to compete effectively against current technology as well as to respond effectively to technological advances.

We are exposed to the credit risk of some of our customers.

Due to the prior slowdown in the economy, the credit risks relating to our customers increased. Although we have programs in place to monitor and mitigate the associated risk, there can be no assurance that such programs will be effective in reducing our credit risks. We have experienced losses due to customers failing to meet their obligations. Although these losses have not been significant, future losses, if incurred, could harm our business and have a material adverse effect on our operating results and financial conditions.

Because we outsource our instrument component, chemical intermediates and product manufacturing, our ability to produce and supply our products could be impaired.

We outsource most of the production of components of our instruments to vendors. We also outsource significant quantities of our high volume chemical intermediates for our consumables products. Our reliance on our outside vendors exposes us to risks including:

•

the possibility that one or more of our vendors could terminate their services at any time without notice;

•

reduced control over pricing, quality and timely delivery, due to the difficulties in switching to alternative vendors; and

•

the potential delays and expenses of seeking alternative sources of manufacturing services.

Consequently, in the event that components from our suppliers or work performed by our vendors are delayed or interrupted for any reason, our ability to produce and deliver our products in sufficient quantities and at acceptable costs would decline. Additionally, certain components are provided by a single source. The effect of a disruption of delivery of those single source components could impact our ability to deliver product to our customers.

We may face litigation from some of our stockholders that might be costly to resolve.

We have received correspondence from a stockholder claiming that our Board of Directors wasted corporate funds, breached their fiduciary duty and otherwise took actions contrary to Delaware law. Such claims may result in our being involved in

Page 15 of 23

litigation. Although we believe that these claims are without merit, we cannot assure you that these or additional claims will not result in litigation in the future or that any lawsuits will not be successful. We could incur substantial costs and diversion of management resources to defend any lawsuit, which could harm our business. In addition, we may be obligated under our charter documents and written indemnification agreements to indemnify our management and directors for legal fees and other costs incurred in defending any such lawsuits. Legal fees and costs in connection with any litigation are likely to be substantial.

We are exposed to fluctuations in the exchange rates of foreign currency and the U.S. dollar.

As a global concern, we face exposure to adverse movements in foreign currency and U.S. dollar exchange rates. During the nine months ended September 30, 2004, approximately 56% of our net sales were exposed to foreign currency risk. During the same period, approximately 24% of our operating expenses were exposed to foreign currency risk. These exposures may change over time as business practices evolve and could have a material adverse impact on our financial results. We will monitor our exposure and may hedge against this and any other emerging market currencies as necessary.

Our business is subject to risks from international operations.

We conduct business globally. Accordingly, our future results could be materially adversely affected by a variety of uncontrollable and changing factors including, among others, foreign currency exchange rates; regulatory, political, or economic conditions in a specific country or region; trade protection measures and other regulatory requirements; and natural disasters. Any or all of these factors could have a material adverse impact on our future international business.

Our business is subject to the effects of general global economic conditions, and particularly economic conditions in the United States and the United Kingdom. Specifically, our business is subject to the effects of market conditions in the pharmaceutical, biotechnology, life sciences and chemical industries. In recent quarters, our operating results have been adversely affected as a result of unfavorable economic conditions and reduced capital spending in the United States, Europe, and Asia. If the economic conditions in the United States and globally do not improve, or if we experience a worsening in the global economic slowdown, we may continue to experience material adverse impacts on our business, operating results, and financial condition.

If we infringe on or misappropriate the proprietary rights of others or we are unable to protect our own intellectual property rights our revenues could be harmed.

We may be sued for infringing on the intellectual property rights of others. Intellectual property litigation is costly, and, even if we prevail, the cost of such litigation could affect our profitability. In addition, litigation is time consuming and could divert management attention and resources away from our business. If we do not prevail in any litigation, in addition to any damages we might have to pay, we could be required to stop the infringing activity or obtain a license. We may not be able to obtain required licenses on acceptable terms, or at all. In addition, some licenses may be nonexclusive, and therefore, our competitors may have access to the technology licensed to us. If we fail to obtain a required license or are unable to design around a patent, we may be unable to sell some of our products, which could harm our ability to compete and result in a decline in our revenues.

Our success may depend on our ability to obtain and enforce patents on our technology and to protect our trade secrets. Any patents we own may not afford meaningful protection for our technology and products. Others may challenge our patents and, as a result, our patents could be narrowed, invalidated or rendered unenforceable. In addition, our current and future patent applications may not result in the issuance of patents to us in the United States or foreign countries. Moreover, competitors may develop products similar to ours that are not covered by our patents.

We try to protect our non-patented trade secrets by requiring our employees, consultants and advisors to execute confidentiality agreements. However, we cannot guarantee that these agreements will provide us with adequate protection against improper use or disclosure of our trade secrets. Further, others may independently develop substantially equivalent proprietary information and techniques. If we are unable to protect our proprietary information and techniques, our ability to exclude certain competitors from the market will be limited.

There may not be an active, liquid trading market for our common stock.

We are listed on the NASDAQ National Market. There is no guarantee that an active trading market for our Common Stock will be maintained on the NASDAQ National Market. You may not be able to sell your shares quickly or at the market price

Page 16 of 23

if trading in our stock is not active. If we fail to comply with the continued listing requirements of the NASDAQ National Market, we may be de-listed from trading on such market, and thereafter trading in our common stock, if any, would likely be conducted through the NASDAQ SmallCap Market, the over-the-counter market or on the Electronic Bulletin Board of the National Association of Securities Dealers, Inc. On October 19, 2004 we received a notice from the NASDAQ Stock Market stating that we are currently out of compliance with the minimum per share requirement for continued listing on the NASDAQ National Market and that we have until April 18, 2005 to regain compliance.

Our stock price has been highly volatile, and your investment could suffer a further decline in value.

The trading price of our common stock has been highly volatile and ranged in 2004 from a per-share high of $2.68 to a low of $0.89 and could continue to be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, including;

•

actual or anticipated variations in quarterly operating results;

•

failure to achieve, or changes in, financial estimates by securities analysts;

•

announcements of new products or services or technological innovations by us or our competitors;

•

conditions or trends in the pharmaceutical, biotechnology, life sciences and chemical industries;

•

announcements by us of significant acquisitions, strategic partnerships, joint ventures or capital commitments;

•

additions or departures of key personnel, including any directors;

•

developments in the application or interpretation of new or existing accounting pronouncements and reporting obligations;

•

purchases or sales of our common stock, including any repurchases of our common stock under the existing or future stock repurchase program; and

•

developments regarding our patents or other intellectual property or that of our competitors.

In addition, the stock market in general, and the NASDAQ Stock Market’s National Market and SmallCap Market and the market for technology companies in particular, have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Further, there has been particular volatility in the market prices of securities of life science companies. These broad market and industry factors may negatively impact the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs, potential liabilities and the diversion of management’s attention and resources.

Recently Enacted and Proposed Changes in Securities Laws and Regulations are Likely to Increase Our Costs

The Sarbanes-Oxley Act of 2002 that became law in July 2002 requires changes in some of our corporate governance and securities disclosure or compliance practices. That Act also requires the SEC to promulgate new rules on a variety of subjects, in addition to rule proposals already made, and Nasdaq has proposed revisions to its requirements for companies that are Nasdaq-listed. We expect these developments to increase our legal compliance costs, and to make some activities more time-consuming. We are presently evaluating and monitoring regulatory developments and cannot estimate the timing or magnitude of additional costs we may incur as a result.

Legislative Actions, Potential New Accounting Pronouncements and Higher Compliance Costs are Likely to Adversely Impact Our Future Financial Position and Results of Operations.

Future changes in financial accounting standards, including the possibility that we will be required to expense all stock option grants and other stock-based compensation to employees, may cause adverse, unexpected earnings fluctuations and affect our financial position and results of operations. New accounting pronouncements and varying interpretations of such pronouncements have occurred with frequency in the recent past and may occur in the future. In addition we may make changes in our accounting policies in the future. Compliance with changing regulation of corporate governance and public disclosure will also result in additional expenses. Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002, new SEC regulations and Nasdaq National Market listing requirements, are creating uncertainty for companies such as ours and compliance costs are increasing as a result of this uncertainty and other factors. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, we intend to invest all reasonably necessary resources to comply with evolving standards, and this investment will result in increased general and administrative expenses and may cause a diversion of management time and attention from revenue-generating activities to compliance activities.

Page 17 of 23

Sales of large numbers of shares of our common stock could cause our stock price to decline.

The market price of our common stock could decline as a result of sales of substantial amounts of our common stock in the public market, or the perception that these sales could occur. In addition, these factors could make it more difficult for us to raise funds through future offerings of common stock. All of the shares sold in our initial public offering are now freely transferable without restriction or further registration under the Securities Act, except for any shares purchased by our affiliates, as defined in Rule 144 of the Securities Act. The remaining shares of common stock outstanding are restricted securities as defined in Rule 144. These shares may be sold in the future without registration under the Securities Act, to the extent permitted by Rule 144 or other exemptions under the Securities Act.

On March 1, 2001, we issued 666,667 shares of unregistered common stock in connection with the acquisition of ATSI.

On February 5, 2002, we registered 2,628,618 shares of common stock that are reserved for issuance upon exercise of options granted under our stock option and employee stock purchase plans. These shares can be sold in the public market upon issuance, subject to restrictions under the securities laws applicable to resales by affiliates.

On February 20, 2002, we issued 572,152 shares of unregistered common stock in connection with the acquisition of Jones Group.

We face risks associated with past and future acquisitions.

Our success depends in part on our ability to continually enhance and broaden our product offerings in response to changing technologies, customer demands and competitive pressures. To meet these challenges, we have acquired complementary businesses and may choose to acquire others in the future.

We do not know if we will be able to complete any future acquisitions, or whether we will be able to successfully integrate any acquired business, operate it profitably or retain its key employees. Integrating any business, product or technology we acquire could be expensive and time consuming, and may disrupt our ongoing business and distract our management. If we are unable to effectively integrate any acquired entities, products or technologies, our business may suffer. In addition, any amortization of goodwill or other assets or charges resulting from the costs of acquisitions could negatively impact our operating results. Our available cash and securities may be used to buy or invest in companies or products, possibly resulting in significant acquisition-related charges to earnings and dilution to our stockholders. Due to volatile market conditions, the value of long live assets may be negatively impacted, which may result in future, additional impairment charges. Moreover, if we buy a company, we may have to incur or assume that company’s liabilities, including liabilities that are unknown at the time of acquisition.

Anti-takeover provisions in our charter, bylaws and Preferred Stock Rights Agreement and under Delaware law could make a third-party acquisition of us difficult.

Our certificate of incorporation, bylaws and Stockholder Rights Plan contain provisions that could make it more difficult for a third party to acquire us, even if doing so might be deemed beneficial by our stockholders. These provisions could limit the price that investors might be willing to pay in the future for shares of our common stock. We are also subject to certain provisions of Delaware law that could delay, deter or prevent a change in control of us.

The rights issued pursuant to our Preferred Stock Rights Agreement will become exercisable the tenth day after a person or group announces acquisition of 10% or more of our common stock or announces commencement of a tender or exchange offer the consummation of which would result in ownership by the person or group of 10 % or more of our common stock. If the rights become exercisable, the holders of the rights (other than the person acquiring 10 % or more of our common stock) will be entitled to acquire, in exchange for the rights’ exercise price, shares of our common stock or shares of any company in which we are merged, with a value equal to twice the rights’ exercise price.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

During the second quarter of 2004, we repaid in full, the notes payable that were denominated in British Pound Sterling in the amount of £7,650,000 related to the acquisition of the Jones Group. With the exception of this event, our market risk disclosures have not changed significantly from those set forth in the Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission on March 30, 2004.

Page 18 of 23

Condition and Results of Operations in our Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission on March 30, 2004.

ITEM 4. CONTROLS AND PROCEDURES

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of its Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of its disclosure controls and procedures. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures as defined in Rules 13(a)-14(c) under the Securities Exchange Act of 1934 (“Exchange Act”) are effective to ensure that information required to be disclosed by the Company in this report and other reports that it files under the Exchange Act is recorded, processed, summarized and reported within the periods specified in SEC rules and forms. It should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

There have been no significant changes in our internal controls over financial reporting that occurred during our most recent fiscal quarter that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.

PART II. OTHER INFORMATION

ITEM 1: LEGAL PROCEEDINGS

The Company is not currently involved in any material legal proceedings.

ITEM 2: UNREGISTERED SALES OF SECURITIES AND USE

Company Purchases of Common Stock

The following table provides information about purchases by the Company for the nine months ended September 30, 2004 of our common stock:

Page 19 of 23

	1.		All purchases were made pursuant to our publicly announced repurchase program.
	2.		On August 8, 2002, we announced the approval by our Board of Directors of a stock repurchase program under which we may repurchase up to $500,000 of our outstanding common stock through open market transactions. The duration of our stock repurchase program is open-ended and the timing and amount of repurchase transactions under this program will depend on market conditions, corporate and regulatory considerations, and will be funded from available working capital.

ITEM 3: DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5: OTHER INFORMATION

None.

ITEM 6: EXHIBITS

(a) Exhibits.

     The following exhibits have been filed with this report.

Page 20 of 23

(b) Reports on Form 8-K.

	On	July 29, 2004, the Company filed a report on Form 8-K providing the contents of a press release issued by the Company announcing its financial results for the quarter ended June 30, 2004.
	On	August 6, 2004, the Company filed a report on Form 8-K providing the contents of a letter written by Lissa Goldenstein, CEO of the Company, to Seymour Holtzman, Chairman of Jewelcor Companies, in response to a letter sent by Mr. Holtzman.

   The Company filed no other reports on Form 8-K during the period ended September 30, 2004.

Page 21 of 23

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Page 22 of 23

ARGONAUT TECHNOLOGIES, INC.
FORM 10-K
Quarterly Period Ended September 30, 2004

EXHIBIT INDEX

Page 23 of 23